Table 1. Patient demographics of the included trials.

Source	Tan et al. [28]	Johnson et al. [29]	Chu et al. [30]	Johnson et al. [18]
Year of publication	2017	2003	2003	1997
Size (n)	302	110	209	35
Gender (M/F)	168/134	75/35	Unclear	18/17
Age (years)	44.2	35.0 a	Unclear	36.6
Disease	MDR-TB	TB	TB b	MDR-TB
Initial drug resistance	Isoniazid and rifampin	No	No	Isoniazid and rifampin
New or retreatment	New, relapse	New	Retreatment	Retreatment
HIV	Seronegative	Seronegative	Seronegative	Seronegative
Comorbidities	Unclear	Unclear	Unclear	Unclear
Center	14 multicenter	Single center	Unclear	Single center
Region	China	Uganda	China	South Africa

M/F: male/female; TB: tuberculosis; MDR-TB: multidrug-resistant tuberculosis; HIV: human immunodeficiency virus.

^a median.

^b 85 patients were MDR-TB.